Recent studies have demonstrated that the activation of the STING pathway by agonists can elicit downstream immune responses, such as the production of interferons (IFNs) and proinflammatory cytokines, and the activation of natural killer (NK) cells and T cells, ultimately leading to the mitigation of cancer progression.17 Here, STING1 is linked to cancer.